{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:49:57Z","timestamp":1760100597093,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Fran\u00e7aises d'Anesth\u00e9sie et de R\u00e9animation"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.annfar.2013.05.007","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T22:17:44Z","timestamp":1376432264000},"page":"659-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Utilisation hors AMM du facteur VII activ\u00e9 recombinant (Novoseven\u00ae) \u00e0 l\u2019AP\u2013HP en 2010"],"prefix":"10.1016","volume":"32","author":[{"given":"J.","family":"Bardon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"de Montblanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-F.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sarrut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annfar.2013.05.007_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.midw.2008.01.008","article-title":"Saving mothers\u2019 lives (formerly why mothers die): reviewing maternal deaths to make motherhood safer 2003\u20132005","volume":"24","author":"Mander","year":"2008","journal-title":"Midwifery"},{"key":"10.1016\/j.annfar.2013.05.007_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jss.2012.05.054","article-title":"Revisiting early postinjury mortality: are they bleeding because they are dying or dying because they are bleeding?","volume":"179","author":"Morton","year":"2012","journal-title":"J Surg Res"},{"issue":"Suppl. 2","key":"10.1016\/j.annfar.2013.05.007_bib0015","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00134-002-1471-7","article-title":"Updates in the management of severe coagulopathy in trauma patients","volume":"28","author":"Lynn","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.annfar.2013.05.007_bib0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.TA.0000171453.37949.B7","article-title":"Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials","volume":"59","author":"Boffard","year":"2005","journal-title":"J Trauma"},{"key":"10.1016\/j.annfar.2013.05.007_bib0025","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/cc8943","article-title":"Management of bleeding following major trauma: an updated European guideline","volume":"14","author":"Rossaint","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.annfar.2013.05.007_bib0030","doi-asserted-by":"crossref","first-page":"R120","DOI":"10.1186\/cc5026","article-title":"Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding\u00a0\u2013\u00a0a European perspective","volume":"10","author":"Vincent","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.annfar.2013.05.007_bib0035","doi-asserted-by":"crossref","first-page":"R178","DOI":"10.1186\/cc5133","article-title":"Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials","volume":"10","author":"Rizoli","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.annfar.2013.05.007_bib0040","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/00016340600855839","article-title":"Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use","volume":"85","author":"Sobieszczyk","year":"2006","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.annfar.2013.05.007_bib0045","first-page":"389","article-title":"Critical bleeding in pregnancy: a novel therapeutic approach to bleeding","volume":"72","author":"Baudo","year":"2006","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.annfar.2013.05.007_bib0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/GRF.0b013e3181cc4378","article-title":"The use of recombinant activated FVII in postpartum hemorrhage","volume":"53","author":"Franchini","year":"2010","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.annfar.2013.05.007_bib0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1479-828X.2007.00823.x","article-title":"Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage","volume":"48","author":"Welsh","year":"2008","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.annfar.2013.05.007_bib0060","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/ACO.0b013e3283532007","article-title":"The role of recombinant activated factor VII in obstetric hemorrhage","volume":"25","author":"Ahonen","year":"2012","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.annfar.2013.05.007_bib0065","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1213\/ANE.0b013e3181c039e6","article-title":"Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry","volume":"109","author":"Phillips","year":"2009","journal-title":"Anesth Analg"},{"key":"10.1016\/j.annfar.2013.05.007_bib0070","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/bja\/aei244","article-title":"Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study","volume":"95","author":"Diprose","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.annfar.2013.05.007_bib0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1537-2995.2005.04216.x","article-title":"Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis","volume":"45","author":"Karkouti","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.annfar.2013.05.007_bib0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/JBM.S21609","article-title":"Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery","volume":"2","author":"Barua","year":"2011","journal-title":"J Blood Med"},{"key":"10.1016\/j.annfar.2013.05.007_bib0085","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00005373-200104000-00021","article-title":"Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries","volume":"50","author":"Martinowitz","year":"2001","journal-title":"J Trauma"},{"key":"10.1016\/j.annfar.2013.05.007_bib0090","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00005373-200208000-00011","article-title":"The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries","volume":"53","author":"Schreiber","year":"2002","journal-title":"J Trauma"},{"key":"10.1016\/j.annfar.2013.05.007_bib0095","first-page":"CD009052","article-title":"Methods to decrease blood loss and transfusion requirements for liver transplantation","author":"Gurusamy","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.annfar.2013.05.007_bib0100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1053\/j.gastro.2004.07.015","article-title":"Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.annfar.2013.05.007_bib0105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1542-3565(03)00295-7","article-title":"Recombinant activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices","volume":"2","author":"Romero-Castro","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.annfar.2013.05.007_bib0110","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/003655201750422701","article-title":"Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices","volume":"36","author":"Ejlersen","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.annfar.2013.05.007_bib0115","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.athoracsur.2007.06.076","article-title":"Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry","volume":"85","author":"Dunkley","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.annfar.2013.05.007_bib0120","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/lt.20710","article-title":"Use of recombinant factor VIIa during orthotopic liver transplantation","volume":"12","author":"De Gasperi","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.annfar.2013.05.007_bib0125","first-page":"1174","article-title":"Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII","volume":"101","author":"Bouwmeester","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.annfar.2013.05.007_bib0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4037\/ajcc2006.15.4.399","article-title":"Successful use of recombinant factor VIIa for treatment of severe postpartum hemorrhage","volume":"15","author":"Hamaekers","year":"2006","journal-title":"Am J Crit Care"},{"key":"10.1016\/j.annfar.2013.05.007_bib0135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1757-1626-1-361","article-title":"Successful use of recombinant activated factor VII for postoperative associated haemorrhage: a case report","volume":"1","author":"Vlachos","year":"2008","journal-title":"Cases J"},{"key":"10.1016\/j.annfar.2013.05.007_bib0140","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/0003-4819-154-8-201104190-00002","article-title":"Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records","volume":"154","author":"Logan","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annfar.2013.05.007_bib0145","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1160\/TH09-09-0667","article-title":"Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey","volume":"103","author":"Bergmann","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.annfar.2013.05.007_bib0150","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.purol.2008.02.005","article-title":"\u00c9valuation des pratiques professionnelles\u00a0: audit portant sur l\u2019antibioprophylaxie en urologie","volume":"18","author":"Malavaud","year":"2008","journal-title":"Prog Urol"},{"key":"10.1016\/j.annfar.2013.05.007_bib0155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-154-8-201104190-00004","article-title":"Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications","volume":"154","author":"Yank","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annfar.2013.05.007_bib0160","first-page":"489","article-title":"Results of the CONTROL trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage","volume":"69","author":"Hauser","year":"2010","journal-title":"J Trauma"},{"key":"10.1016\/j.annfar.2013.05.007_bib0165","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.jvca.2011.03.004","article-title":"Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis","volume":"25","author":"Ponschab","year":"2011","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.annfar.2013.05.007_bib0170","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of recombinant activated factor VII in randomized clinical trials","volume":"363","author":"Levi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annfar.2013.05.007_bib0175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ajog.2011.06.009","article-title":"Cutting-edge advances in the medical management of obstetrical hemorrhage","volume":"205","author":"Pacheco","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.annfar.2013.05.007_bib0180","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/CIRCULATIONAHA.108.764308","article-title":"Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery","volume":"118","author":"Karkouti","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.annfar.2013.05.007_bib0185","first-page":"1314","article-title":"Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery","volume":"40","author":"Chapman","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annfar.2013.05.007_bib0190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.108.834275","article-title":"Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery","volume":"120","author":"Gill","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.annfar.2013.05.007_bib0195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.jvca.2008.08.003","article-title":"Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes","volume":"23","author":"Masud","year":"2009","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.annfar.2013.05.007_bib0200","first-page":"1320","article-title":"Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23\u00a0French cardiac centres (2005\u20137)","volume":"40","author":"Hacquard","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annfar.2013.05.007_bib0205","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(03)12268-4","article-title":"Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial","volume":"361","author":"Friederich","year":"2003","journal-title":"Lancet"}],"container-title":["Annales Fran\u00e7aises d'Anesth\u00e9sie et de R\u00e9animation"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0750765813002219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0750765813002219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:19:30Z","timestamp":1760091570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0750765813002219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0750765813002219"],"URL":"https:\/\/doi.org\/10.1016\/j.annfar.2013.05.007","relation":{},"ISSN":["0750-7658"],"issn-type":[{"type":"print","value":"0750-7658"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilisation hors AMM du facteur VII activ\u00e9 recombinant (Novoseven\u00ae) \u00e0 l\u2019AP\u2013HP en 2010","name":"articletitle","label":"Article Title"},{"value":"Annales Fran\u00e7aises d'Anesth\u00e9sie et de R\u00e9animation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annfar.2013.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}